Bristol-Myers Squibb (NYSE:BMY) Stock Position Lessened by Gilman Hill Asset Management LLC

Gilman Hill Asset Management LLC decreased its position in shares of Bristol-Myers Squibb (NYSE:BMYFree Report) by 6.0% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 218,237 shares of the biopharmaceutical company’s stock after selling 13,901 shares during the period. Bristol-Myers Squibb accounts for approximately 2.1% of Gilman Hill Asset Management LLC’s portfolio, making the stock its 3rd largest holding. Gilman Hill Asset Management LLC’s holdings in Bristol-Myers Squibb were worth $12,343,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Annex Advisory Services LLC lifted its stake in shares of Bristol-Myers Squibb by 6.0% during the fourth quarter. Annex Advisory Services LLC now owns 6,796 shares of the biopharmaceutical company’s stock valued at $384,000 after buying an additional 384 shares during the period. Grove Bank & Trust lifted its stake in shares of Bristol-Myers Squibb by 14.9% during the fourth quarter. Grove Bank & Trust now owns 18,550 shares of the biopharmaceutical company’s stock valued at $1,049,000 after buying an additional 2,407 shares during the period. Brady Martz Wealth Solutions LLC purchased a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $239,000. Clarius Group LLC lifted its stake in shares of Bristol-Myers Squibb by 10.0% during the fourth quarter. Clarius Group LLC now owns 15,541 shares of the biopharmaceutical company’s stock valued at $879,000 after buying an additional 1,409 shares during the period. Finally, Aaron Wealth Advisors LLC lifted its stake in shares of Bristol-Myers Squibb by 2.5% during the fourth quarter. Aaron Wealth Advisors LLC now owns 90,400 shares of the biopharmaceutical company’s stock valued at $5,113,000 after buying an additional 2,207 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Insider Activity at Bristol-Myers Squibb

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,830 shares of the firm’s stock in a transaction on Friday, November 1st. The shares were purchased at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the transaction, the executive vice president now owns 62,109 shares in the company, valued at $3,395,499.03. This represents a 3.04 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Phil M. Holzer sold 700 shares of Bristol-Myers Squibb stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $55.62, for a total transaction of $38,934.00. Following the completion of the transaction, the senior vice president now owns 11,760 shares in the company, valued at approximately $654,091.20. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.

Bristol-Myers Squibb Stock Performance

BMY opened at $56.35 on Monday. The business’s 50 day moving average is $57.53 and its 200-day moving average is $52.00. The stock has a market cap of $114.30 billion, a PE ratio of -15.70, a price-to-earnings-growth ratio of 1.95 and a beta of 0.45. The company has a current ratio of 1.24, a quick ratio of 1.09 and a debt-to-equity ratio of 2.83. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $61.08.

Bristol-Myers Squibb (NYSE:BMYGet Free Report) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. The company had revenue of $11.89 billion for the quarter, compared to analysts’ expectations of $11.26 billion. Bristol-Myers Squibb had a positive return on equity of 11.94% and a negative net margin of 15.30%. The business’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.00 earnings per share. On average, analysts predict that Bristol-Myers Squibb will post 0.93 earnings per share for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a dividend yield of 4.40%. The ex-dividend date is Friday, January 3rd. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -69.08%.

Wall Street Analysts Forecast Growth

BMY has been the subject of several research analyst reports. Sanford C. Bernstein began coverage on shares of Bristol-Myers Squibb in a research report on Thursday, October 17th. They set a “market perform” rating and a $56.00 price target for the company. TD Cowen lifted their target price on shares of Bristol-Myers Squibb from $53.00 to $59.00 and gave the company a “hold” rating in a report on Monday, October 7th. Daiwa America upgraded Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Daiwa Capital Markets upgraded Bristol-Myers Squibb from a “neutral” rating to an “outperform” rating in a report on Wednesday, November 13th. Finally, Barclays increased their price target on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a report on Monday, October 7th. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $56.27.

View Our Latest Stock Analysis on BMY

About Bristol-Myers Squibb

(Free Report)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.

Recommended Stories

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMYFree Report).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.